Company Filing History:
Years Active: 2014
Title: The Innovative Contributions of Stephen Johnstone
Introduction
Stephen Johnstone is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of neuroendocrine disease treatment. His innovative approach focuses on utilizing non-cytotoxic proteases to target neuroendocrine tumor cells.
Latest Patents
Johnstone holds a patent for the "Suppression of neuroendocrine diseases." This invention relates to a method for suppressing neuroendocrine diseases through the use of a non-cytotoxic protease. The therapy is designed to target neuroendocrine tumor cells via various receptors, including somatostatin, GHRH, and ghrelin receptors. When delivered, the protease is internalized, inhibiting secretion from the tumor cells. Additionally, the invention encompasses polypeptides and nucleic acids for use in these methods. He has 1 patent to his name.
Career Highlights
Throughout his career, Johnstone has worked with prominent companies in the biotechnology sector. He has been associated with Syntaxin Limited and Ipsen Bioinnovation Limited, where he contributed to advancements in medical therapies.
Collaborations
Johnstone has collaborated with notable professionals in his field, including Philip Marks and Keith Foster. Their combined expertise has furthered the development of innovative solutions in neuroendocrine disease treatment.
Conclusion
Stephen Johnstone's work in the suppression of neuroendocrine diseases showcases his commitment to advancing medical science. His innovative methods and collaborations highlight the importance of targeted therapies in treating complex health issues.